Tvardi Therapeutics is trading at $1.25, down 6.02% in pre-market; available evidence does not establish a cause for the September 29 decline.
- No new company-specific announcement or clear catalyst was identified. The latest identified company news was September 24 preclinical data on its STAT3 inhibitor.
- Broader markets were slightly higher in the supplied context and do not clearly explain the decline; recent sessions have shown sharp price swings.
- No reliable volume or activity figure was provided.